Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Instagram Outage Disrupts Thousands of U.S. Users 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
SAN ANTONIO, Texas, Aug. 24, 2016 -- bioAffinity Technologies today announced that it has been awarded a U.S. Patent protecting a proprietary kit that contains the CyPath® assay for the early detection of cancer and the prognosis of patient response to cancer therapy.
The U.S. Patent, entitled “5, 10, 15, 20-Tetrakis (Carboxyphenyl) Porphine (TCPP) and Kit for Use with Detecting Cancer,” relates to the use of the porphyrin-based CyPath® assay for the early detection of dysplastic, pre-cancerous and cancerous cells from tissue samples both in vitro and in situ. CyPath® preferentially binds to cancer cells, giving them a distinctive fluorescence that can be used to detect cancer at an early stage of the disease by an imaging system.
“The newly awarded patent expands our intellectual property estate and provides important protection as we move toward commercialization of our lung cancer assay,” bioAffinity President and CEO Maria Zannes said. “bioAffinity’s current research on the CyPath® diagnostic and our porphyrin-conjugated chemotherapeutic agents for the delivery of drug therapies is reaching beyond product development to provide greater understanding of the fundamental nature of cancer. We are laying the foundation for a game-changing entry into the cancer diagnosis and treatment markets.”
bioAffinity’s patent portfolio includes 42 awarded patents in 21 countries and six patents pending. U.S. Patent 9,417,241 expands on earlier patents for the detection of precancerous, or dysplastic, cells and cancerous cells based on their unique propensity to take up the bioAffinity assay significantly more than healthy cells.
About bioAffinity Technologies
bioAffinity Technologies, Inc. (www.bioaffinitytech.com) is a privately held development-stage company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment. The Company develops proprietary in-vitro diagnostic tests and targeted cancer therapeutics using breakthrough technology that preferentially targets cancer cells. The Company’s platform technology will be developed to diagnose, monitor and treat many cancers. CyPath® Lung, bioAffinity’s initial product, is designed to be the first successful non-invasive, early-stage lung cancer diagnostic on the market.
Contact: Maria Zannes, 505.400.9747
